Predictions
Abiomed Inc.
Start price
Target price
Perf. (%)
€266.84
09.03.18
09.03.18
€306.68
07.05.18
07.05.18
17.78%
07.05.18
07.05.18
Could be worthwhile Investment >10% per year
Sintx Technologies Inc.
Start price
Target price
Perf. (%)
€6,223.8
22.02.18
22.02.18
€7,306.2
06.03.18
06.03.18
18.70%
06.03.18
06.03.18
Magellan Health Services
Start price
Target price
Perf. (%)
€91.51
27.02.18
27.02.18
€92.00
02.03.18
02.03.18
0.54%
02.03.18
02.03.18
Karyopharm Therapeutics Inc.
Start price
Target price
Perf. (%)
€10.96
28.01.18
28.01.18
€12.45
08.02.18
08.02.18
13.66%
08.02.18
08.02.18
Five Prime Therapeutics
Start price
Target price
Perf. (%)
€33.29
03.04.17
03.04.17
€40.59
20.10.17
20.10.17
25.79%
20.10.17
20.10.17
Biolife Solutions Inc
Start price
Target price
Perf. (%)
€2.61
05.07.17
05.07.17
€2.80
14.07.17
14.07.17
27.25%
14.07.17
14.07.17
Melinta Therapeutics Inc.
Start price
Target price
Perf. (%)
€59.19
29.12.16
29.12.16
€94.71
21.06.17
21.06.17
60.00%
21.06.17
21.06.17
Thermo Fisher Scientific Inc.
Start price
Target price
Perf. (%)
€136.85
21.11.16
21.11.16
€150.00
21.02.17
21.02.17
10.28%
21.02.17
21.02.17
Ekso Bionics Holdings Inc.
Start price
Target price
Perf. (%)
€50.51
13.09.16
13.09.16
€60.00
28.09.16
28.09.16
20.94%
28.09.16
28.09.16
Portola Pharmaceuticals Inc.
Start price
Target price
Perf. (%)
€36.33
03.06.15
03.06.15
€40.00
07.12.15
07.12.15
23.06%
07.12.15
07.12.15
Rigel Pharmaceutical Inc.
Start price
Target price
Perf. (%)
€1.55
01.10.14
01.10.14
€2.00
01.04.15
01.04.15
110.38%
01.04.15
01.04.15
Johnson & Johnson
Start price
Target price
Perf. (%)
€86.15
28.11.14
28.11.14
€92.00
23.01.15
23.01.15
6.79%
23.01.15
23.01.15
Could be worthwhile Investment >10% per year
Market Leader or Top 3
Known brand
Future proof or reliable business model
Arena Pharmaceuticals Inc
Start price
Target price
Perf. (%)
€13.18
30.01.12
30.01.12
€30.00
11.05.12
11.05.12
302.12%
11.05.12
11.05.12
Gilead Sciences Inc
Start price
Target price
Perf. (%)
€14.68
27.07.11
27.07.11
€18.00
26.01.12
26.01.12
25.99%
26.01.12
26.01.12
Could be very worthwhile Investment >20% year
Revenue growth >5% per year expected
EBIT growth >5% per year expected
Undervalued